Patients with an anticipated duration of<unk>  longer than 10 days, patients undergoing intensive induction/consolidation therapy for acute leukemias, patients receiving treatment with alemtuzumab-containing regimens, allogeneic HSCT recipients, and those with GVHD following allogeneic HSCT are categorized as high risk for infectious complications.
Febrile neutropenia risk factors
Thrombocytopenia differential diagnosis
Febrile neutropenia diagnostic criteria
Febrile neutropenia causes
Chronic myelogenous leukemia risk factors
Hairy cell leukemia risk factors
B-cell lymphoma risk factors
Thrombocytopenia risk factors